The Patent Finder

Waratah Pharmaceuticals Inc.

Also on record
Records under this name other than the patents Waratah Pharmaceuticals Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Showing 1 to 8 of 8 · Back to Waratah Pharmaceuticals Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,803,766Gastrin compositions and formulations, and methods of use and preparation
Lapsed on the fee record
Ended Sep 28, 2014 · USPTO record
Lapsed on the fee recordEnded Sep 28, 2014USPTO record
US 7,037,504Epidermal growth factor protein and gene, and methods of use therefor
Lapsed on the fee record
Ended May 2, 2014 · USPTO record
Lapsed on the fee recordEnded May 2, 2014USPTO record
US 6,288,301Treatment for juvenile diabetes
Lapsed on the fee record
Ended Sep 11, 2013 · USPTO record
Lapsed on the fee recordEnded Sep 11, 2013USPTO record
US 7,560,425Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
Lapsed on the fee record
Ended Jul 14, 2013 · USPTO record
Lapsed on the fee recordEnded Jul 14, 2013USPTO record
US 7,476,388Composition comprising a gastrin/CCK receptor ligand and an EGF receptor ligand
Lapsed on the fee record
Ended Jan 13, 2013 · USPTO record
Lapsed on the fee recordEnded Jan 13, 2013USPTO record
US 6,558,952Treatment for diabetes
Lapsed on the fee record
Ended May 6, 2011 · USPTO record
Lapsed on the fee recordEnded May 6, 2011USPTO record
US 6,992,060Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes
Lapsed on the fee record
Ended Jan 31, 2010 · USPTO record
Lapsed on the fee recordEnded Jan 31, 2010USPTO record
US 5,885,956Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
Term ended
Term ended no later than Mar 23, 2019 · Low confidence
Term endedTerm ended no later than Mar 23, 2019Low confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited